What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss the case and its connections to their work with the Kraft Precision Medicine Accelerator.
Pursuing Precision Medicine at Intermountain Healthcare | Cold Call podcast - Listen or read transcript on Metacast
